Sign in with your email address username.


[Comment] A LEAN treatment for non-alcoholic steatohepatitis

With the obesity pandemic, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and an important cause of cirrhosis and hepatocellular carcinoma worldwide.1,2 The disease affects 15–40% of the general adult population. Although most cases of NAFLD follow a benign course, up to 20% of cases have non-alcoholic steatohepatitis with active hepatic necroinflammation and injury, which results in progressive liver fibrosis and complications.